# A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

> **NCT05659732** · PHASE1 · RECRUITING · sponsor: **PharmaEngine** · enrollment: 32 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** PEP07

## Key facts

- **NCT ID:** NCT05659732
- **Lead sponsor:** PharmaEngine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-17
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659732, "A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05659732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*